A federal judge has struck a report Takeda Pharmaceuticals U.S.A. filed with the court indicating it was on track to restore evidence in an Actos case that resulted in a $9 billion verdict.

U.S. District Judge Rebecca F. Doherty said the drugmaker’s report was “more in the nature of a motion or argument better saved for appeal” and that its status report should only have been provided directly to a special master.

This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.

To view this content, please continue to their sites.

Not a Lexis Subscriber?
Subscribe Now

Not a Bloomberg Law Subscriber?
Subscribe Now

Why am I seeing this?

LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.

For questions call 1-877-256-2472 or contact us at [email protected]